Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/Oncologymediviewcurative inpatient oncology coverage updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentmediviewcurativePolicy N/A

    Inpatient oncology treatment — induction chemotherapy and stem cell transplant; admission, continued stay, discharge, level-of-care, and documentation criteria

    Customize your policy alerts

    Sign up for all mediviewcurative policy alerts

    Know when mediviewcurative releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines inpatient admission, continued stay, discharge, level-of-care, and documentation criteria for induction chemotherapy (AML, ALL, aggressive lymphoma) and autologous/allogeneic stem cell transplant; intended for utilization management and providers caring for hospitalized oncology patients.

    Policy Summary
    Payermediviewcurative
    PolicyInpatient oncology treatment — induction chemotherapy and stem cell transplant; admission, continued stay, discharge, level-of-care, and documentation criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 4, 2026
    Last ReviewMar 4, 2026
    Next Review DateN/A
    Key ActionDocument daily oncology review and active treatment progress for any continued inpatient stay; include daily CBC/ANC for induction, engraftment assessment for transplant, or CRS/ICANS grading for CAR-T.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10conditions/procedures in this section
    5-7dGoal LOS (induction chemo)
    ANC≥500×2dDischarge ANC threshold
    DRG 018MS-DRG for CAR-T
    21-30 / 30-60dGoal LOS (HSCT auto/allo)

    Coverage Criteria — Admissions, Continued Stay, Discharge, and Extended-Stay

    Admission criteria (Induction chemotherapy / HSCT)

    Admission requires ALL severity elements and ≥1 intensity element

    Severity of Illness (SI): Active oncologic condition requiring inpatient-level monitoring, treatment, or intervention; complication of cancer or cancer treatment that cannot be safely managed outpatient; clinical severity (vital-sign instability, lab abnormalities, organ dysfunction) requiring continuous monitoring; expected treatment duration or monitoring needs requiring ≥2 midnight hospital stay

    All items must be met

    Intensity of Service (IS): Multi-day continuous IV chemotherapy infusion not available outpatient; daily laboratory monitoring required for treatment safety (e.g., TLS prevention, DIC management); blood-product transfusion support (≥2 units or daily platelet requirement); IV medications requiring inpatient monitoring (chemotherapy, immunotherapy, biologics, antifungals); strict neutropenic precautions with HEPA-filtered room; ICU-level monitoring for treatment complications (CRS, ICANS, engraftment syndrome)

    At least one must be met

    Observation vs Inpatient Decision Matrix

    Policy Summary
    Payermediviewcurative
    PolicyInpatient oncology treatment — induction chemotherapy and stem cell transplant; admission, continued stay, discharge, level-of-care, and documentation criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 4, 2026
    Last ReviewMar 4, 2026
    Next Review DateN/A
    Key ActionDocument daily oncology review and active treatment progress for any continued inpatient stay; include daily CBC/ANC for induction, engraftment assessment for transplant, or CRS/ICANS grading for CAR-T.
    SourceLink
    On This Page
    Coverage Criteria — Admissions, Continued Stay, Discharge, and Extended-StayCoding — ICD-10, CPT, MS-DRG, and Revenue CodesProvider Actions — Prior Authorization, Documentation, and Level-of-Care GuidanceCovered Regimens and Supportive TherapiesLine of Therapy DesignationsDefinitions and Grading CriteriaBackground — Scope and Rationale

    Certain scenarios are always inpatient or not inpatient

    Always inpatient: Induction chemotherapy (AML/ALL); stem cell transplant conditioning through engraftment; CAR-T lymphodepletion through CRS monitoring period

    These situations should always be managed as inpatient

    Does not meet inpatient criteria: Cancer diagnosis alone without acute treatment/complication requiring inpatient monitoring; chemotherapy regimens that can be safely administered in outpatient infusion centers; stable chronic cancer pain manageable outpatient; surveillance imaging/staging/workup/elective biopsy; continued stay solely awaiting outpatient scheduling when medically stable for discharge

    These are not sufficient for inpatient status

    Continued stay / Concurrent review

    Continued stay requires daily oncology review and documentation of active treatment progress; continued stay allowed if any listed condition is present

    Daily review requirement: Daily oncology review documenting active treatment with daily progress toward milestones (daily CBC and ANC tracking for chemo induction; daily engraftment assessment for transplant; daily CRS/ICANS grading per ASTCT for CAR-T)

    Required for concurrent review

    Continued stay indications: Active treatment infusing; ANC <500 during expected nadir; active infection; transfusion-dependent; GVHD requiring IV therapy; CRS/ICANS not resolved

    Any one justifies continued inpatient stay

    Discharge criteria

    Discharge when criteria met

    Discharge criteria: Acute treatment completed or condition stable for outpatient management; ANC ≥500 x 2 days (if aplastic) or clear upward trend; transfusion-independent ≥48 hours; tolerating oral medications and adequate nutrition; no active untreated infection requiring IV antibiotics; pain controlled on oral regimen; oncology follow-up with labs within 48–72 hours post-discharge

    All apply to consider safe discharge

    Extended-stay criteria

    Extended stay requires documentation of at least one medical-necessity trigger

    Extended-stay triggers: Persistent febrile neutropenia despite broad-spectrum antibiotics; tumor lysis with continued laboratory abnormalities requiring rasburicase or dialysis; mucositis preventing oral intake with TPN dependence; CRS or ICANS persisting beyond expected duration requiring tocilizumab/anakinra/steroids; graft failure or delayed engraftment (HSCT) beyond expected day +14

    One or more must be documented to extend stay beyond goal LOS

    Level-of-Care grid

    Level of care definitions tie clinical severity to unit placement

    ICU criteria: CRS grade ≥3 requiring vasopressors; ICANS grade ≥3; septic shock from neutropenia; tumor lysis with severe AKI on CRRT; intracranial mass with herniation risk requiring osmotherapy; ventilator support

    ICU-level care indicated

    Stepdown/PCU criteria: CRS grade 2 on tocilizumab; ICANS grade 1–2 requiring frequent neuro checks; febrile neutropenia with hemodynamic concern; tumor lysis on aggressive IV fluids/rasburicase; post-engraftment graft failure monitoring

    Stepdown appropriate

    Med-Surg criteria: Afebrile, ANC recovering, tolerating diet, transitioning IV→PO antibiotics, completing chemotherapy cycle, mucositis improving

    Med-Surg appropriate

    Observation/home/post-acute criteria: Observation generally not applicable for active induction/HSCT/CAR-T (may be used for rapid-recovery chemo when CMS criteria met); home when afebrile, ANC ≥500, tolerating PO, pain controlled with appropriate follow-up or HHA support; post-acute (SNF/IRF/LTAC) for deconditioned post-HSCT/CAR-T patients

    Disposition examples

    CAR-T: Admission, Continued Stay, and Discharge Criteria

    CAR-T therapy inpatient coverage and level-of-care decision logic

    Admission - Severity of Illness (SI): Active oncologic condition requiring inpatient-level monitoring/treatment; complication of cancer or treatment that cannot be safely managed outpatient; clinical severity (vital-sign instability, lab abnormalities, organ dysfunction) requiring continuous monitoring; expected treatment duration or monitoring needs requiring ≥2 midnight hospital stay

    All SI items must be present

    Admission - Intensity of Service (IS): Multi-day continuous IV chemo infusion not available outpatient; daily laboratory monitoring required; blood-product transfusion support (≥2 units or daily platelet requirement); IV medications requiring inpatient monitoring; strict neutropenic precautions with HEPA room; ICU-level monitoring for treatment complications (CRS, ICANS, engraftment syndrome)

    At least one IS item must be met

    Observation vs Inpatient: Always inpatient for induction chemotherapy (AML/ALL), stem cell transplant conditioning through engraftment, and CAR-T lymphodepletion through CRS monitoring period

    These admissions should be authorized as inpatient

    Continued stay (concurrent review): Daily oncology review with active treatment documented and daily progress toward milestones; continued stay if active treatment infusing, ANC <500 during expected nadir, active infection, transfusion-dependent, GVHD requiring IV therapy, or CRS/ICANS not resolved

    Use ASTCT CRS/ICANS grading for CAR-T

    Discharge criteria: Acute treatment completed or condition stable for outpatient management; ANC ≥500 x 2 days or clear upward trend; transfusion-independent ≥48 hours; tolerating oral medications and adequate nutrition; no active untreated infection requiring IV antibiotics; pain controlled on oral regimen; oncology follow-up with labs within 48–72 hours post-discharge

    Discharge when all are met

    HSCT: Admission, LOS Goals, and Extended-Stay Criteria

    HSCT inpatient coverage and extended-stay guidance

    MS-DRG and LOS guidance: MS-DRG crosswalk provided for allogeneic and autologous BMT (DRG 014–017); goal LOS for uncomplicated cases: autologous 21–30 days, allogeneic 30–60 days

    Sources: ASTCT/EBMT Standards 2023; CMS MS-DRG 014–017

    Admission SI/IS for HSCT: Severity: active oncologic condition requiring inpatient monitoring/treatment; complication not manageable outpatient; clinical severity requiring continuous monitoring; expected duration ≥2 midnights. Intensity: multi-day IV chemo, daily labs, transfusion support, IV meds requiring monitoring, HEPA room, or ICU-level monitoring for complications

    Admission requires SI and ≥1 IS

    Extended-stay medical-necessity triggers: Persistent febrile neutropenia despite broad-spectrum antibiotics; tumor lysis with continued lab abnormalities requiring rasburicase or dialysis; mucositis preventing oral intake with TPN dependence; CRS/ICANS persisting beyond expected duration requiring tocilizumab/anakinra/steroids; graft failure or delayed engraftment beyond expected day +14

    One or more must be documented; include specific trigger, evidence, and intervention plan

    Chemotherapy-Induced Complications: Admission/Stay/Discharge

    Admission, continued-stay and discharge criteria for severe chemotherapy-induced complications

    Admission SI for chemo complications: Must meet ≥1 severity criterion: active oncologic condition requiring inpatient-level monitoring/treatment; complication of cancer or treatment that cannot be safely managed outpatient; clinical severity (vital-sign instability, lab abnormalities, organ dysfunction) requiring continuous monitoring; expected treatment duration or monitoring needs requiring ≥2 midnight hospital stay

    At least one SI required

    IS for chemo complications: Must meet ≥1 intensity criterion: multi-day continuous IV chemo not available outpatient; daily lab monitoring required; blood-product transfusion support (≥2 units or daily platelet need); IV medications requiring inpatient monitoring; strict neutropenic precautions (HEPA); ICU-level monitoring for complications

    At least one IS required

    Continued stay triggers: Daily oncology review; continued stay if active treatment infusing; ANC <500 during expected nadir; active infection; transfusion-dependent; GVHD requiring IV therapy; CRS/ICANS not resolved

    Any one justifies continued inpatient stay

    Discharge criteria for chemo complications: Acute treatment completed or condition stable for outpatient management; ANC ≥500 x 2 days or clear upward trend; transfusion-independent ≥48 hours; tolerating oral meds and adequate nutrition; no active untreated infection requiring IV antibiotics; pain controlled on oral regimen; oncology follow-up with labs within 48–72 hours post-discharge

    All apply to consider safe discharge

    Continued-stay (general)

    Continued inpatient stay is covered when ALL of the following daily-review and active-treatment conditions are met:

    Continued stay requirements: Daily oncology review documenting active treatment with daily progress toward milestones; for chemo induction: daily CBC with ANC nadir/recovery tracking; for transplant: daily engraftment assessment; for CAR-T: daily CRS/ICANS grading per ASTCT criteria

    Required documentation for concurrent review

    Continued-stay (triggers & extended-stay)

    Continued stay is covered if ANY of the following are present:

    Continued-stay triggers: Active treatment being infused; ANC <500 during expected nadir; active infection; transfusion-dependence; GVHD requiring IV therapy; unresolved CRS/ICANS

    Any one supports ongoing inpatient care

    Extended-stay medical necessity triggers: Persistent febrile neutropenia despite broad-spectrum antibiotics; tumor lysis with continued laboratory abnormalities requiring rasburicase or dialysis; mucositis preventing oral intake with TPN dependence; CRS/ICANS persisting beyond expected duration requiring tocilizumab/anakinra/steroids; graft failure or delayed engraftment beyond expected day +14

    One or more must be documented when Goal LOS exceeded

    Admission criteria (GVHD / general inpatient oncology)

    Admission for acute GVHD is covered when BOTH Severity of Illness (SI) and Intensity of Service (IS) criteria are met as specified:

    Severity of Illness (SI): Must meet ≥1: active oncologic condition requiring inpatient-level monitoring/treatment/intervention; complication of cancer or cancer treatment that cannot be safely managed outpatient; clinical severity (vital-sign instability, lab abnormalities, organ dysfunction) requiring continuous monitoring; expected treatment duration/monitoring requiring ≥2 midnights

    At least one SI criterion required

    Intensity of Service (IS): Must meet ≥1: multi-day continuous IV chemotherapy infusion unavailable outpatient; daily lab monitoring required for treatment safety (e.g., TLS prevention, DIC management); blood-product transfusion support (≥2 units or daily platelet requirement); IV medications requiring inpatient monitoring (chemo, immunotherapy, biologics, antifungals); strict neutropenic precautions with HEPA-filtered room (allogeneic transplant); ICU-level monitoring for treatment complications (CRS, ICANS, engraftment syndrome)

    At least one IS criterion required

    Observation vs Inpatient

    Admission level decision matrix — ALWAYS inpatient for specified scenarios; NOT inpatient when only listed outpatient-manageable conditions are present:

    Always inpatient: Induction chemotherapy (AML/ALL); stem-cell transplant conditioning through engraftment; CAR-T lymphodepletion through CRS monitoring period

    These are always inpatient per decision matrix

    Does not meet inpatient criteria: Cancer diagnosis alone without acute treatment/complication requiring inpatient monitoring; chemotherapy regimens safely administered outpatient; stable chronic cancer pain manageable outpatient; surveillance imaging/staging/workup/elective biopsy; continued stay solely awaiting outpatient scheduling when medically stable for discharge

    These are exclusions to inpatient admission

    Discharge criteria

    Patients are appropriate for discharge when ALL of the following are met:

    Discharge requirements: Acute treatment completed or condition stable for outpatient management; ANC ≥500 for 2 days or clear upward trend (if aplastic); transfusion-independent ≥48 hours; tolerating oral medications and adequate nutrition; no active untreated infection requiring IV antibiotics; pain controlled on oral regimen; oncology follow-up with labs within 48–72 hours post-discharge

    All criteria support safe transition to next level of care

    Initial admission — Oncologic pain crisis / palliative

    Admission is covered when ALL of the following SI/IS logic is met:

    Oncologic pain crisis admission

    • Severity of Illness (SI): Must meet ≥2 of: active oncologic condition requiring inpatient-level monitoring/treatment/intervention; complication of cancer or cancer treatment not safely managed outpatient; clinical severity (vital-sign instability, lab abnormalities, organ dysfunction) requiring continuous monitoring; expected treatment duration or monitoring needs requiring ≥2-midnight hospital stay
    • Intensity of Service (IS): Must meet ≥1 of: multi-day continuous IV chemotherapy infusion not available outpatient; daily laboratory monitoring required for treatment safety; blood-product transfusion support (≥2 units or daily platelet requirement); IV medications requiring inpatient monitoring (chemotherapy, immunotherapy, biologics, antifungals); strict neutropenic precautions with HEPA-filtered room; ICU-level monitoring for treatment complications

    Initial admission — Brain metastases with cerebral edema

    Admission is covered when ALL of the following SI/IS logic is met:

    Brain mets with cerebral edema admission

    • Severity of Illness (SI): Must meet ≥1 of: active oncologic condition requiring inpatient-level monitoring/treatment/intervention; complication of cancer or cancer treatment not safely managed outpatient; clinical severity (vital-sign instability, lab abnormalities, organ dysfunction) requiring continuous monitoring; expected treatment duration or monitoring needs requiring ≥2-midnight hospital stay
    • Intensity of Service (IS): Must meet ≥1 of: multi-day continuous IV chemotherapy infusion not available outpatient; daily laboratory monitoring required for treatment safety; blood-product transfusion support (≥2 units or daily platelet requirement); IV medications requiring inpatient monitoring; strict neutropenic precautions with HEPA-filtered room; ICU-level monitoring for treatment complications

    Continued stay / concurrent review (brain metastases / edema)

    Continued inpatient stay is covered when daily oncology review documents active treatment or one or more clinical conditions persist:

    Continued stay triggers: Covered if any of the following: active treatment infusing; ANC <500 during expected nadir; active infection; transfusion-dependent; GVHD requiring IV therapy; CRS/ICANS not resolved; or other condition requiring inpatient interventions as listed

    Daily oncology review must document active treatment and progress

    Discharge criteria (brain metastases / edema)

    Discharge appropriate when ALL of the following are met or as specified:

    Discharge criteria: Acute treatment completed or condition stable for outpatient management; ANC ≥500 x 2 days (if aplastic) or clear upward trend; transfusion-independent ≥48 hours; tolerating oral medications and adequate nutrition; no active untreated infection requiring IV antibiotics; pain controlled on oral regimen; oncology follow-up with labs within 48–72 hours post-discharge

    All criteria required for safe discharge

    Level-of-care grid (brain metastases / edema)

    Level of care placement examples based on severity and resource needs:

    Level-of-care indications: ICU for CRS grade ≥3, ICANS grade ≥3, septic shock from neutropenia, tumor lysis with severe AKI on CRRT, intracranial mass with herniation risk needing osmotherapy, ventilator support; Stepdown for CRS grade 2 on tocilizumab or ICANS grade 1–2 needing frequent neuro checks, febrile neutropenia with hemodynamic concern; Med-Surg for afebrile, ANC recovering, tolerating diet; Observation generally not applicable for active induction/HSCT/CAR-T; Home when afebrile, ANC ≥500, tolerating PO, pain controlled, with appropriate follow-up or HHA support

    Examples map clinical severity to unit placement

    Extended stay criteria (brain metastases / edema)

    When Goal LOS is exceeded, continued inpatient stay requires documentation of ONE OR MORE of the following triggers:

    Extended stay triggers: Persistent febrile neutropenia despite broad-spectrum antibiotics; tumor lysis with continued laboratory abnormalities requiring rasburicase or dialysis; mucositis preventing oral intake with TPN dependence; CRS or ICANS persisting beyond expected duration requiring tocilizumab/anakinra/steroids; graft failure or delayed engraftment (HSCT) beyond expected day +14

    One or more must be documented to justify extended stay; include specific trigger, supporting evidence, and targeted intervention plan

    Admission — SI/IS criteria

    Admission — SI/IS criteria

    Severity of Illness (SI): Must meet ≥1: active oncologic condition requiring inpatient-level monitoring/treatment/intervention; complication of cancer or treatment that cannot be safely managed outpatient; clinical severity (vital-sign instability, lab abnormalities, organ dysfunction) requiring continuous monitoring; expected treatment duration or monitoring requiring ≥2 midnights≥1

    Source: admission criteria sections

    Intensity of Service (IS): Must meet ≥1: multi-day continuous IV chemotherapy infusion not available outpatient; daily laboratory monitoring required for treatment safety (e.g., TLS prevention, DIC management); blood-product transfusion support (≥2 units or daily platelet requirement); IV medications requiring inpatient monitoring; strict neutropenic precautions with HEPA-filtered room; ICU-level monitoring for treatment complications (CRS, ICANS, engraftment syndrome)≥1

    Source: intensity-of-service sections

    Observation vs Inpatient (general oncology section)

    Observation vs inpatient decision matrix — items that ALWAYS require inpatient care and items that DO NOT meet inpatient criteria:

    Always inpatient: Induction chemotherapy (AML/ALL); stem cell transplant conditioning through engraftment; CAR-T lymphodepletion through CRS monitoring periodall

    Always inpatient per decision matrix

    Does not meet criteria: Cancer diagnosis alone without acute treatment/complication requiring inpatient monitoring; chemotherapy safely administered outpatient; stable chronic cancer pain manageable outpatient; surveillance imaging/staging/workup/elective biopsy; continued stay solely awaiting outpatient scheduling when medically stable for discharge≥1

    Exclusions to inpatient admission

    Continued stay (general oncology section)

    Continued stay/concurrent review — continued inpatient stay requires ongoing active treatment or unresolved high-risk conditions:

    Continued stay conditions: Active treatment infusing; ANC <500 during expected nadir; active infection; transfusion-dependent; GVHD requiring IV therapy; unresolved CRS/ICANS≥1

    Daily oncology review required documenting progress toward milestones

    Discharge criteria (general oncology section)

    Discharge criteria — safe transition to next level of care requires all of the following:

    Discharge requirements: Acute treatment completed or condition stable for outpatient management; ANC ≥500 x 2 days (if aplastic) or clear upward trend; transfusion-independent ≥48 hours; tolerating oral medications and adequate nutrition; no active untreated infection requiring IV antibiotics; pain controlled on oral regimen; oncology follow-up with labs within 48–72 hours post-dischargeall

    All items required for discharge

    Extended stay — medical necessity triggers

    Extended stay triggers — one or more must be documented to justify stay beyond goal LOS:

    Extended stay triggers: Persistent febrile neutropenia despite broad-spectrum antibiotics; tumor lysis with continued laboratory abnormalities requiring rasburicase or dialysis; mucositis preventing oral intake with TPN dependence; CRS or ICANS persisting beyond expected duration requiring tocilizumab/anakinra/steroids; graft failure or delayed engraftment beyond expected day +14≥1

    Document specific trigger, clinical evidence, and targeted intervention plan

    Admission criteria (radiation-induced complications)

    Admission criteria (radiation-induced complications)

    Admission SI for radiation-induced complications: Must meet ≥1: active oncologic condition requiring inpatient-level monitoring/treatment/intervention; complication of cancer or treatment that cannot be safely managed outpatient; clinical severity (vital-sign instability, lab abnormalities, organ dysfunction) requiring continuous monitoring; expected treatment duration or monitoring needs requiring ≥2 midnight hospital stay

    SI criteria for radiation-induced complications

    Admission IS for radiation-induced complications: Must meet ≥1: multi-day continuous IV chemotherapy infusion not available outpatient; daily laboratory monitoring required; blood-product transfusion support (≥2 units or daily platelet requirement); IV medications requiring inpatient monitoring; strict neutropenic precautions with HEPA-filtered room; ICU-level monitoring for treatment complications

    IS criteria for radiation-induced complications

    Observation vs Inpatient decision (radiation-induced complications)

    Observation vs Inpatient decision (radiation-induced complications)

    Always inpatient: Induction chemotherapy (AML/ALL); stem cell transplant conditioning through engraftment; CAR-T lymphodepletion through CRS monitoring period

    Always inpatient per matrix

    Does not meet inpatient criteria: Cancer diagnosis alone without acute treatment/complication requiring inpatient monitoring; chemotherapy regimens safely administered outpatient; surveillance imaging/staging/workup/elective biopsy; continued stay solely awaiting outpatient scheduling when medically stable for discharge

    These do not meet inpatient criteria

    Continued stay criteria (radiation-induced complications)

    Continued stay criteria (radiation-induced complications)

    Daily review and active treatment documentation: Daily oncology review required with active treatment documented and daily progress toward milestones (examples provided for chemo induction, transplant, CAR-T)

    Concurrent review requirement

    Conditions supporting continued stay: Active treatment infusing; ANC <500 during expected nadir; active infection; transfusion-dependent; GVHD requiring IV therapy; unresolved CRS/ICANS

    Any one justifies continued inpatient care

    Extended stay criteria (radiation-induced complications)

    Extended stay criteria (radiation-induced complications)

    Extended-stay medical necessity triggers: Persistent febrile neutropenia despite broad-spectrum antibiotics; tumor lysis with continued laboratory abnormalities requiring rasburicase or dialysis; mucositis preventing oral intake with TPN dependence; CRS or ICANS persisting beyond expected duration requiring tocilizumab/anakinra/steroids; graft failure or delayed engraftment beyond expected day +14

    One or more must be documented when Goal LOS exceeded

    Discharge criteria (radiation-induced complications)

    Discharge criteria (radiation-induced complications)

    Discharge requirements: Acute treatment completed or condition stable for outpatient management; ANC ≥500 x 2 days or clear upward trend; transfusion-independent ≥48 hours; tolerating oral medications and adequate nutrition; no active untreated infection requiring IV antibiotics; pain controlled on oral regimen; oncology follow-up with labs within 48–72 hours post-discharge

    All items required for safe discharge

    As described in the decision matrix, admissions for surveillance imaging, staging workup, elective biopsy, or for a continued stay solely awaiting outpatient scheduling when the patient is medically stable for discharge do not meet inpatient criteria and should be managed outpatient whenever feasible. The policy explicitly lists these items as examples of care that "DOES NOT MEET CRITERIA" for inpatient status and therefore are not valid justifications for inpatient admission.

    The policy also notes that chemotherapy regimens that can be safely administered in an outpatient infusion center and stable chronic cancer pain manageable with outpatient adjustments are not appropriate reasons for inpatient admission. Providers should document when inpatient-level monitoring or intensity of service (e.g., multi-day continuous IV infusions, daily labs, transfusion support, ICU-level monitoring) is required to support admission; absence of those inpatient-level needs favors outpatient management.

    A cancer diagnosis alone — without an accompanying acute treatment need, treatment complication, or clinical instability that requires continuous inpatient monitoring — is not sufficient to justify inpatient admission. The policy repeatedly lists "Cancer diagnosis alone without acute treatment or complication requiring inpatient monitoring" as an item that "DOES NOT MEET CRITERIA."

    Practical examples cited by the policy include patients who only require surveillance imaging or staging workup, those who have diagnoses for which chemotherapy can safely be given in an outpatient infusion center, and patients with stable chronic cancer pain who can be managed with outpatient pain adjustments. In these situations, observation or outpatient pathways should be used rather than inpatient admission unless additional Severity of Illness or Intensity of Service criteria are met and documented.

    Coding — ICD-10, CPT, MS-DRG, and Revenue Codes

    Covered ICD-10 Diagnosis Codes — leukemias and lymphomas (partial list)ICD-10Covered
    C91.00ALL not achieved remission
    C91.01ALL in remission
    C91.02ALL in relapse
    C92.00AML not achieved remission
    C92.01AML in remission
    C92.02AML in relapse
    C92.40acute promyelocytic leukemia not achieved remission
    C92.41APL in remission
    C92.42APL in relapse
    C92.50AML with multilineage dysplasia not achieved remission
    1–10 of 33
    1/4
    Covered ICD-10 Diagnosis Codes — lymphomas and treatment encountersICD-10Covered
    C83.33intra-abdominal
    C83.34lymph nodes axilla/upper limb
    C83.35lymph nodes inguinal/lower limb
    C83.36intrapelvic
    C83.37spleen
    C83.38lymph nodes multiple sites
    C83.39extranodal/solid organ sites
    C83.70Burkitt lymphoma unspecified site
    C83.71head/neck
    C83.72intrathoracic
    1–10 of 23
    1/3
    HSCT-related ICD-10 and CPT codesmixedCovered
    Z94.84Stem cell transplant status
    T86.00BMT rejection unspecified
    T86.01BMT rejection
    T86.02BMT failure
    T86.03BMT infection
    T86.09Other complication of BMT
    T86.5Stem cell transplant complication
    D89.810Acute GVHD
    D89.811Chronic GVHD
    D89.812Acute on chronic GVHD
    1–10 of 18
    1/2
    MS-DRG crosswalksRevenue
    DRG 834-836Acute Leukemia w/o Major OR
    DRG 837-839Chemo with Acute Leukemia as secondary
    DRG 840-842Lymphoma/Non-Acute Leukemia
    DRG 014Allogeneic BMT
    DRG 016Autologous BMT w CC/MCC
    DRG 017Autologous BMT w/o CC/MCC
    HSCT DRG and CPT Codesmixed
    DRG 014Allogeneic BMT
    DRG 016Autologous BMT w CC/MCC
    DRG 017Autologous BMT w/o CC/MCC
    CPT 38240Allogeneic bone marrow transplant (allo)
    CPT 38241Autologous bone marrow transplant (auto)
    CAR-T DRG and HCPCS Codesmixed
    DRG 018CAR-T and Other Immunotherapies
    HCPCS Q2041Yescarta
    HCPCS Q2042Kymriah
    HCPCS Q2053Tecartus
    HCPCS Q2054Breyanzi
    HCPCS Q2055Abecma
    HCPCS Q2056Carvykti
    ICD-10 Codes for CAR-T, Lymphomas, HSCT Indications, and Chemo ComplicationsICD-10
    Z51.12Encounter for antineoplastic immunotherapy
    C83.30-C83.39DLBCL codes (various sites)
    C83.70-C83.79Burkitt lymphoma codes (various sites)
    C85.10-C85.19B-cell NHL
    C91.00-C91.02B-cell ALL codes
    C90.00-C90.02Multiple myeloma codes
    C82.00-C82.99Follicular lymphoma
    C84.60-C84.69Anaplastic large cell lymphoma
    K12.31Oral mucositis due to antineoplastic therapy
    T45.1X5AAdverse effect of antineoplastic/immunosuppressive drugs
    1–10 of 14
    1/2
    ICD-10-PCS CAR-T Procedure CodesICD-10-PCS
    XW033C7Introduction of CAR-T into peripheral vein, percutaneous
    XW043C7Introduction of CAR-T into central vein
    MS-DRG & Revenue codes (chemotherapy-induced complications)mixed
    DRG 840-842Lymphoma/Leukemia complications
    DRG 917-918Poisoning/Toxic Effects
    DRG 640-642Metabolic
    Rev 0335Revenue code example
    Rev 0250Revenue code example
    Rev 0390Revenue code example
    MS-DRG & Revenue codes (GVHD)mixed
    DRG 814-816Reticuloendothelial/Immunity Disorders
    DRG 840-842If underlying malignancy
    Rev 0250Steroids, ruxolitinib, immunosuppressants
    Rev 0636Revenue code example
    ICD-10-CM codes (Oncologic pain crisis / palliative admission)ICD-10Covered
    G89.3Neoplasm related pain
    R52Pain, unspecified
    C00-C96Underlying malignancy
    Z51.5Encounter for palliative care
    G89.0Central pain syndrome
    G89.4Chronic pain syndrome
    ICD-10-CM codes (GVHD and complications)ICD-10Covered
    D89.810Acute graft-versus-host disease
    D89.811Chronic graft-versus-host disease
    D89.812Acute on chronic graft-versus-host disease
    D89.813GVHD unspecified
    T86.00Unspecified complication of bone marrow transplant
    T86.01Bone marrow transplant rejection
    T86.02Bone marrow transplant failure
    T86.03Bone marrow transplant infection
    T86.09Other complications of bone marrow transplant
    K52.21Food protein-induced enterocolitis (if GI GVHD)
    1–10 of 12
    1/2
    Oncologic pain crisis / palliative admission ICD-10ICD-10
    G89.3neoplasm related pain
    R52pain unspecified
    C00-C96underlying malignancy
    Z51.5encounter for palliative care
    G89.0central pain syndrome
    G89.4chronic pain syndrome
    Brain metastases with cerebral edema ICD-10ICD-10
    C79.31secondary malignant neoplasm of brain
    C79.32secondary malignant neoplasm of cerebral meninges
    C79.40secondary malignant neoplasm of unspecified part of nervous system
    G93.6cerebral edema
    G91.0-G91.9hydrocephalus
    MS-DRG & Revenue codes (oncologic pain)mixed
    DRG 091-093Other Disorders of Nervous System (when G89.3 PDx)
    Rev 0250PCA opioids, ketamine, nerve blocks
    Rev 0420Physical Therapy
    Rev 0940palliative consult
    MS-DRG & Revenue codes (brain metastases)mixed
    DRG 054-056Nervous System Neoplasms
    DRG 023-027If surgical (craniotomy)
    Rev 0250dexamethasone
    Rev 0330radiation therapy
    Rev 0610MRI
    Rev 0360OR
    ICD-10 for malignant pleural/peritoneal effusionICD-10
    J91.0malignant pleural effusion
    C78.2secondary malignant neoplasm of pleura
    C78.6secondary malignant neoplasm of retroperitoneum and peritoneum
    R18.0malignant ascites
    C48.1malignant neoplasm of peritoneum (part)
    C48.2malignant neoplasm of peritoneum (part)
    Procedures and DRGs for malignant pleural/peritoneal effusionmixedCovered
    32556thoracentesis
    32550PleurX catheter
    32440pleurodesis
    DRG 186-188Pleural Effusion
    DRG 163-165Major Chest Procedures (if VATS)
    ICD-10 for pathologic fracture from metastatic diseaseICD-10
    M84.40XApathological fracture unspecified site initial
    M84.411Apathological fracture shoulder initial
    M84.419Apathological fracture shoulder initial (range end)
    M84.421Apathological fracture humerus initial
    M84.429Apathological fracture humerus initial (range end)
    M84.431Apathological fracture ulna/radius initial
    M84.439Apathological fracture ulna/radius initial (range end)
    M84.441Apathological fracture hand initial
    M84.449Apathological fracture hand initial (range end)
    M84.451Apathological fracture femur initial
    1–10 of 21
    1/3
    DRGs and revenue codes for pathologic fracturemixedCovered
    DRG 542-544Pathological Fractures/Musculoskeletal Neoplasms
    DRG 480-482Hip/Femur Procedures (if surgical stabilization)
    Rev 0330radiation revenue
    Rev 0360operating room revenue
    Rev 0610MRI revenue
    MS-DRG & Revenue (pathological fracture)mixed
    542-544MS-DRG Pathological Fractures/Musculoskeletal Neoplasms
    480-482MS-DRG Hip/Femur Procedures (if surgical stabilization)
    0330Revenue code radiation
    0360Revenue code OR
    0610Revenue code MRI
    MS-DRG & Revenue (radiation-induced complications)mixed
    177-179DRG Respiratory (radiation-induced)
    391-393DRG GI (radiation-induced)
    091-093DRG Neurological (radiation-induced)
    0250Revenue code steroids, immunosuppressants
    0350Revenue code CT
    0610Revenue code MRI
    ICD-10-CM codes (radiation-induced complications)ICD-10Covered
    J70.0Radiation pneumonitis, acute
    J70.1Radiation pneumonitis, chronic
    K52.0Radiation gastroenteritis and colitis
    K62.7Radiation proctitis
    G62.82Radiation-induced polyneuropathy
    G95.0Syringomyelia and syringobulbia
    G95.89Other specified diseases of spinal cord - radiation myelopathy
    Y84.2Radiological procedure as cause of abnormal reaction
    Expected inpatient stay — criteria
    Expected inpatient stay≥2 midnights
    Admission SI requirementAll SI items must be met: active oncologic condition; complication not manageable outpatient; clinical severity needing continuous monitoring; expected duration/monitoring requiring ≥2 midnights
    Admission IS examplesAt least one IS required: multi-day continuous IV chemo not available outpatient; daily labs for treatment safety; blood-product transfusion support (≥2 units or daily platelet requirement)
    Discharge ANC threshold
    Discharge ANC thresholdANC ≥500 for 2 days (or clear upward trend)
    Discharge clinical requirementsAcute treatment completed or condition stable for outpatient management; tolerating oral meds and adequate nutrition
    Follow-up and infection controlNo active untreated infection requiring IV antibiotics; oncology follow-up with labs within 48–72 hours post-discharge
    Transfusion support — threshold
    Transfusion support thresholdBlood-product transfusion support defined as ≥2 units or daily platelet requirement
    IS examples including transfusionIS includes multi-day continuous IV chemo, daily lab monitoring, IV meds requiring inpatient monitoring, strict neutropenic precautions
    Continued-stay implicationOngoing transfusion dependence supports continued inpatient stay until transfusion-independence criteria met
    ANC required for discharge
    ANC for discharge (applies across sections)ANC ≥500 for 2 days or clear upward trend
    Discharge additional requirementsTransfusion-independent ≥48 hours; tolerating oral medications and adequate nutrition; no active untreated infection requiring IV antibiotics
    Daily review documentationDaily oncology review and documentation of ANC trend required during inpatient course and for discharge decision-making
    Transfusion independence for discharge
    Transfusion independence for dischargeTransfusion-independent for ≥48 hours prior to discharge
    Combined hematologic thresholdsDischarge when ANC ≥500 x2 days (or clear upward trend) AND transfusion-independence ≥48h, plus clinical stability
    Rationale for continued stayIf transfusion dependence persists or ANC <500 during expected nadir, continued inpatient stay is supported until thresholds met

    Provider Actions — Prior Authorization, Documentation, and Level-of-Care Guidance

    Note

    Utilization management and review

    This section is internal utilization-management criteria; automated approvals may be used but all denials require licensed clinician review.

    Billing Rule

    CAR‑T coding and high‑cost therapy mapping

    CAR‑T and other high-cost cellular immunotherapies are mapped to DRG 018 and HCPCS codes Q2041–Q2042, Q2053–Q2056; these items represent high-cost therapies and may require prior authorization or special handling.

    • Mapped MS‑DRG: DRG 018 (CAR‑T and Other Immunotherapies).
    • HCPCS: Q2041, Q2042, Q2053, Q2054, Q2055, Q2056.
    Prior Authorization

    Always‑inpatient treatments (apply inpatient authorization)

    Indications that should always be managed as inpatient include induction chemotherapy (AML/ALL), stem‑cell transplant conditioning through engraftment, and CAR‑T lymphodepletion through the CRS monitoring period.

    • Authorize as inpatient when documentation supports induction chemotherapy (AML/ALL).
    • Authorize as inpatient for HSCT conditioning through engraftment.
    • Authorize as inpatient for CAR‑T lymphodepletion through CRS monitoring period.
    Prior Authorization

    Inpatient‑required therapies — authorization required

    Admissions for induction chemotherapy (AML/ALL), HSCT conditioning through engraftment, and CAR‑T lymphodepletion require inpatient authorization when documented.

    • Document treatment plan and SI/IS criteria to support inpatient authorization.
    Prior Authorization

    Admission requires SI and/or IS criteria

    Admission requires demonstration of Severity of Illness (SI) (all SI elements) and at least one Intensity of Service (IS) element to meet inpatient criteria.

    • SI: active oncologic condition requiring inpatient monitoring; complication not manageable outpatient; clinical severity requiring continuous monitoring; expected ≥2 midnights.
    • IS (≥1): multi‑day continuous IV chemo not available outpatient; daily labs; transfusion support (≥2 units or daily platelet need); IV meds needing inpatient monitoring; HEPA neutropenic precautions; ICU‑level monitoring for complications.
    Prior Authorization

    Prior authorization — admission criteria must be documented

    Prior authorization for inpatient admission requires documentation that the member meets SI and/or IS criteria such as need for multi‑day continuous IV chemotherapy unavailable outpatient, daily laboratory monitoring, transfusion support, or ICU‑level monitoring.

    • Ensure the record documents which SI/IS elements are met and the treatment plan.
    • For CAR‑T/HSCT, include expected monitoring needs and anticipated ≥2‑midnight stay where applicable.
    Step Therapy

    Step therapy

    No step‑therapy requirements are specified in this excerpt.

    Prior Authorization

    Intensity‑of‑Service admission requirements

    Intensity‑of‑Service criteria must be met to justify inpatient admission (examples: multi‑day continuous IV chemotherapy not available outpatient; daily lab monitoring; blood transfusion support; IV medications requiring inpatient monitoring; HEPA room; ICU‑level monitoring).

    • At least one IS element must be documented to support inpatient level of care.
    Documentation Required

    Daily monitoring and concurrent review requirements

    Daily oncology review is required for continued inpatient stay and must document active treatment and daily progress; for induction chemotherapy this includes daily CBC with ANC nadir/recovery tracking, for transplant daily engraftment assessment, and for CAR‑T daily CRS/ICANS grading.

    • Document daily CBC/ANC for induction chemo (track nadir and recovery).
    • Document daily engraftment assessments for HSCT.
    • Document daily CRS/ICANS grading (ASTCT) for CAR‑T patients.
    Billing Rule

    Billing crosswalk guidance (MS‑DRG / revenue codes)

    MS‑DRG and revenue code crosswalks are provided to support billing and level‑of‑care decisions; use the listed DRG groupings (e.g., DRG 091‑093 for neurologic when G89.3 PDx, DRG 014‑017 for HSCT, DRG 018 for CAR‑T) when mapping high‑cost therapies and admissions.

    • Map CAR‑T to DRG 018 and listed HCPCS for therapy-level billing.
    • Use HSCT DRG 014‑017 for transplant admissions where applicable.
    Note

    Level‑of‑care (LOC) based escalation guidance

    Level‑of‑care escalation is tied to objective clinical thresholds: ICU for CRS grade ≥3 or ICANS grade ≥3; stepdown for CRS grade 2 after tocilizumab or ICANS grade 1–2 with frequent neuro checks, etc.

    • Escalate to ICU when CRS ≥3 or ICANS ≥3 (vasopressors, ventilator, organ support).
    • Consider stepdown/PCU for CRS grade 2 on tocilizumab or hemodynamic concern with febrile neutropenia.
    Documentation Required

    Extended‑stay documentation — required elements

    When Goal LOS is exceeded, providers must document one or more specific medical‑necessity triggers, the clinical evidence supporting the trigger, and a targeted intervention plan (e.g., persistent febrile neutropenia despite broad‑spectrum antibiotics; tumor lysis requiring rasburicase or dialysis; mucositis with TPN dependence; persistent CRS/ICANS; graft failure/delayed engraftment).

    • Identify and describe the exact extended‑stay trigger.
    • Provide clinical data (labs, cultures, imaging) supporting the trigger.
    • Document the planned targeted intervention(s) and expected timeline.
    Documentation Required

    Admission documentation requirements

    Admission documentation must include the active oncologic condition, the treatment plan, and clinical severity indicators; record which SI and IS elements are met (for example: multi‑day IV chemo required, daily labs, transfusion needs, or ICU‑level monitoring).

    • Include treatment plan specifying expected monitoring needs and anticipated LOS (≥2 midnights if expected).
    • Document transfusion requirements, ICU needs, and inability to safely manage outpatient.
    Documentation Required

    Extended stay documentation requirements (detail)

    When Goal LOS is exceeded the provider must document the specific extended‑stay trigger, supporting clinical evidence, and a targeted intervention plan — one or more of the listed triggers must be present to justify continued stay.

    • Examples of triggers: persistent febrile neutropenia, tumor lysis needing rasburicase/dialysis, TPN‑dependent mucositis, persistent CRS/ICANS, graft failure or delayed engraftment beyond expected day +14.
    Documentation Required

    Concurrent review documentation — daily oncology review

    Concurrent review requires daily oncology assessment documenting active treatment and daily progress toward milestones; for chemo induction include daily CBC/ANC trends, for transplant daily engraftment measures, and for CAR‑T daily CRS/ICANS grading.

    • Daily notes must reference objective data (CBC/ANC, engraftment labs, CRS/ICANS grades) and planned next steps.
    • Use documented progress to support continued inpatient status.
    Documentation Required

    Extended‑stay documentation (provider must specify trigger & plan)

    Repeated: When Goal LOS is exceeded the provider must document the specific trigger with supporting clinical evidence and a targeted intervention plan to justify continued inpatient stay.

    Documentation Required

    Concurrent review documentation — objective daily monitoring

    Concurrent review must document daily oncology review with active treatment and daily progress (examples: daily CBC/ANC for chemo induction; daily engraftment assessment for transplant; daily CRS/ICANS grading for CAR‑T).

    • Record objective milestones (ANC trend, transfusion independence, engraftment markers) each day.
    Documentation Required

    Extended‑stay documentation — clinical evidence & intervention plan required

    When Goal LOS is exceeded continued inpatient stay requires documentation of one or more specific medical‑necessity triggers, the clinical evidence supporting the trigger, and the targeted intervention plan (documented in the medical record).

    Denial Risk

    Observation vs inpatient decision — denials likely if only cancer diagnosis present

    Inpatient admission will not be supported when the only reason is a cancer diagnosis without acute treatment or complication requiring inpatient monitoring; surveillance imaging, staging/workup, elective biopsy, chemotherapy safely given outpatient, or continued stay solely awaiting outpatient scheduling are not sufficient.

    • Avoid inpatient coding/authorization when care can be safely provided outpatient.
    • Document acute treatment or complication if claiming inpatient necessity.
    Denial Risk

    Admission/stay denial triggers — common denial scenarios

    Admissions may be denied when the sole reason is a cancer diagnosis without acute treatment or a complication requiring inpatient monitoring; similarly, admissions for chemotherapy that can be safely administered outpatient or continued stay solely awaiting outpatient scheduling may be denied.

    • Ensure documentation shows acute treatment need, IS elements, or SI indicators to avoid denial.
    Denial Risk

    Observation vs inpatient — denial risk when inpatient criteria not met

    Admission not meeting inpatient criteria (for example: cancer diagnosis alone without acute treatment/complication, or chemotherapy safely given outpatient) may be denied as inpatient level of care.

    • If inpatient status is requested, document which SI/IS criteria are met and the treatment plan.
    Denial Risk

    Observation vs inpatient — denial triggers (examples)

    Admissions may be denied when the cancer diagnosis alone is present without acute treatment or complication requiring inpatient monitoring, or when chemotherapy can be safely administered outpatient; continued stay solely awaiting outpatient scheduling is also a denial trigger.

    Denial Risk

    Admission/observation criteria — denial risk summary

    Admission may be denied when cancer diagnosis alone without acute treatment or complication is the sole reason, or for continued stay solely awaiting outpatient scheduling while medically stable for discharge.

    Note
    Note
    Note
    Note
    Note

    Covered Regimens and Supportive Therapies

    Regimen / InterventionCoverage StatusNotes / Indication
    Any induction chemotherapy for AML, ALL, or aggressive lymphoma (inpatient administration)
    CAR‑T lymphodepletion and immediate post‑lymphodepletion monitoring period (through CRS/ICANS observation)
    Multi‑day continuous IV chemotherapy infusions that cannot be safely administered outpatient
    Regimen / ProcedureCoverage StatusNotes / Indication
    Autologous hematopoietic stem cell transplant (conditioning through engraftment)
    Allogeneic hematopoietic stem cell transplant (conditioning through engraftment)
    Associated inpatient supportive care (daily engraftment assessment, transfusion support, neutropenic precautions)
    Medication / InterventionCoverage StatusNotes / Indication
    {"text":"Tocilizumab","status":"covered",""}
    {"text":"Anakinra","status":"covered",""}
    {"text":"Systemic corticosteroids (per ASTCT guidance)","status":"covered",""}
    InterventionCoverage StatusNotes / Indication
    Aggressive intravenous (IV) fluids for tumor lysis management
    Rasburicase for tumor lysis with laboratory abnormalities
    Dialysis (including CRRT) when required for tumor lysis–related severe AKI or metabolic derangements

    Line of Therapy Designations

    first-line

    First-line — induction and other regimens requiring inpatient-level care

    Induction chemotherapy: Inpatient is always required for induction chemotherapy for AML/ALL

    First-line induction described

    salvage

    Salvage — HSCT conditioning and engraftment

    HSCT conditioning and engraftment: Inpatient required for stem cell transplant conditioning through engraftment (autologous and allogeneic)

    Per HSCT section

    first-line

    First-line — therapies that always require inpatient monitoring

    Indications always requiring inpatient care: Induction chemotherapy (AML/ALL), stem cell transplant conditioning through engraftment, and CAR-T lymphodepletion through CRS monitoring period must be inpatient

    First-line inpatient regimens

    first-line

    First-line — inpatient-required regimens

    Inpatient-required regimens: Induction chemotherapy for AML/ALL; stem-cell transplant conditioning through engraftment; CAR-T lymphodepletion through CRS monitoring period

    Authorize as inpatient when documented

    first-line

    First-line — inpatient-required therapies (summary)

    Always inpatient: Induction chemotherapy (AML/ALL); stem cell transplant conditioning through engraftment; CAR-T lymphodepletion through CRS monitoring period

    These admissions typically require authorization as inpatient-level care

    salvage

    Salvage — CAR-T and transplant mapping in observation matrix

    CAR-T and transplant: Induction chemotherapy (AML/ALL), stem cell transplant conditioning through engraftment, and CAR-T lymphodepletion through CRS monitoring period are always inpatientall

    Observation vs inpatient matrix

    first-line

    First-line — always inpatient therapies (concise)

    Always inpatient therapies: Induction chemotherapy for AML/ALL; stem cell transplant conditioning through engraftment; CAR-T lymphodepletion through CRS monitoring period

    Policy-defined always-inpatient list

    Definitions and Grading Criteria

    inv-107: ASTCT criteria — CRS/ICANS grading
    ASTCT referenceCRS and ICANS are graded per ASTCT consensus criteria and used daily to guide level‑of‑care decisions.
    Operational useASTCT grading is referenced for CAR‑T monitoring and for directing ICU vs stepdown vs med‑surg placement.
    DocumentationPolicy requires daily CRS/ICANS grading (ASTCT) for CAR‑T during concurrent review and continued‑stay assessment.
    inv-108: ≥2 midnight hospital stay — expected inpatient stay
    DefinitionAn expected inpatient stay is one requiring ≥2 midnights, listed under Severity of Illness admission criteria.
    Applies toInduction chemotherapy, HSCT conditioning, and CAR‑T lymphodepletion monitoring periods.
    Decision impactHelps determine inpatient versus observation status in the policy's decision matrix.
    inv-109: ICU-level care for CRS/ICANS — indications
    ICU indications for CRS/ICANSICU‑level care indicated for CRS grade ≥3 requiring vasopressors or ICANS grade ≥3; also for septic shock from neutropenia, tumor lysis with severe AKI on CRRT, intracranial mass with herniation risk requiring osmotherapy, or ventilator support.
    Related examplesThese ICU triggers are used across CAR‑T, HSCT, and other high‑risk inpatient oncology scenarios in the LOC grid.
    Source guidanceLOC grid cites NCCN, IDSA/NCCN febrile neutropenia, ASTCT/EBMT HSCT Standards, and ASTCT CRS/ICANS consensus as sources for ICU criteria.
    inv-110: Intensity of Service (IS) — definition and examples
    DefinitionIntensity of Service (IS) denotes resource or treatment intensity requiring inpatient setting (examples include multi‑day continuous IV chemotherapy not available outpatient; daily laboratory monitoring; blood‑product transfusion support; IV medications requiring inpatient monitoring; strict neutropenic precautions; ICU‑level monitoring).
    Admission roleMeeting ≥1 IS criterion supports inpatient admission when combined with SI requirements per policy.
    ExamplesSpecifically lists multi‑day IV chemo, daily labs for TLS/DIC prevention, transfusion support (≥2 units or daily platelets), IV immunotherapies/antifungals, HEPA‑filtered rooms, and ICU monitoring for complications.
    inv-111: CRS/ICANS grading (detailed)
    CRS grading useCRS is graded per ASTCT consensus and used daily to guide level‑of‑care decisions and treatment escalation (e.g., tocilizumab, anakinra, steroids).
    ICANS grading useICANS graded per ASTCT criteria and informs neuro monitoring frequency, stepdown vs ICU placement, and therapeutic interventions.
    Clinical requirementPolicy mandates daily CRS/ICANS grading for CAR‑T patients during concurrent review and continued‑stay evaluation.
    inv-112: Severity of Illness (SI) — definition and examples
    DefinitionSeverity of Illness (SI) refers to clinical factors requiring inpatient‑level monitoring, treatment, or intervention (e.g., active oncologic condition, complications not manageable outpatient, vital‑sign instability, organ dysfunction, or expected ≥2‑midnight stay).
    Admission implicationAll SI elements must be met (diagnosis + treatment plan) for admission under SI in many policy sections (e.g., induction, CAR‑T).
    ExamplesIncludes active oncologic condition, treatment complications, hemodynamic instability, lab abnormalities, organ dysfunction and expected prolonged monitoring needs.
    inv-113: Intensity of Service (IS) — definition and examples (repeat)
    IS definition (concise)Intensity of Service (IS) indicates required inpatient resources or treatments such as multi‑day IV infusions, daily labs, transfusion support, inpatient‑only IV meds, neutropenic precautions, or ICU monitoring.
    Admission roleAt least one IS item is required (in many admission criteria) to justify inpatient care when combined with SI elements.
    Common examplesMulti‑day continuous IV chemotherapy, daily lab monitoring (TLS/DIC), ≥2 units transfusion or daily platelets, IV immunotherapy/antifungal infusions, HEPA rooms.
    inv-114: CRS/ICANS grading (ASTCT criteria) — mapping for LOC decisions
    ASTCT mapping for LOCASTCT CRS/ICANS grading is used to map neurologic status to LOC: ICANS grade ≥3 indicates ICU; grade 1–2 may warrant stepdown with frequent neuro checks; CRS grade ≥3 with vasopressors indicates ICU placement.
    Operational impactThis mapping informs escalation (ICU vs stepdown) and triggers use of tocilizumab, steroids, or anakinra per policy.
    DocumentationDaily ASTCT grading is required for CAR‑T concurrent review to support LOC decisions and continued‑stay justification.
    inv-115: Radiation-induced complications — examples and codes
    ExamplesRadiation‑induced complications include radiation pneumonitis (J70.0/J70.1), radiation gastroenteritis (K52.0), radiation proctitis (K62.7), and radiation myelopathy (G95.89).
    CodingPolicy lists specific ICD‑10‑CM codes for radiation‑induced complications to guide diagnosis coding and admission reasoning.
    Clinical contextRadiation complications are included among inpatient oncology indications when they cause organ dysfunction or require inpatient interventions.
    inv-116: Level-of-Care (LOC) Grid — standardized mapping to LOC settings
    PurposeLevel‑of‑Care (LOC) Grid standardizes mapping of objective clinical states to care settings (ICU, stepdown/PCU, med‑surg, observation, post‑acute, home).
    Key mappingsICU for CRS grade ≥3/ICANS grade ≥3, stepdown for CRS grade 2 or ICANS grade 1–2 needing frequent neuro checks, med‑surg for afebrile/ANC recovering patients, observation generally not applicable for induction/HSCT/CAR‑T.
    SourcesLOC Grid references NCCN Hematologic Malignancies, IDSA/NCCN Febrile Neutropenia 2018, ASTCT/EBMT HSCT Standards 2023, and ASTCT CRS/ICANS Consensus 2019.

    Background — Scope and Rationale

    Induction chemotherapy for acute leukemias and aggressive lymphomas, as well as stem cell transplant conditioning through engraftment (autologous and allogeneic) and CAR‑T lymphodepletion through the CRS monitoring period, are designated by the policy as therapies that always require inpatient-level monitoring. These treatments commonly involve multi-day continuous IV infusions, predictable periods of profound cytopenias and neutropenia, potential for rapid clinical decompensation (febrile neutropenia, tumor lysis syndrome, organ dysfunction), and need for frequent laboratory surveillance, transfusion support, and prompt access to ICU-level interventions when complications (e.g., CRS/ICANS) occur.

    Because of those risks, the policy requires inpatient admission when active induction, HSCT conditioning/engraftment care, or CAR‑T lymphodepletion with CRS monitoring is planned — ensuring continuous nursing, immediate lab/biochemistry monitoring, blood-product availability, and rapid escalation to higher levels of care if needed.